Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ANIFROLUMAB Cause Product dose omission issue? 12 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Product dose omission issue have been filed in association with ANIFROLUMAB (SAPHNELO). This represents 3.2% of all adverse event reports for ANIFROLUMAB.

12
Reports of Product dose omission issue with ANIFROLUMAB
3.2%
of all ANIFROLUMAB reports
0
Deaths
6
Hospitalizations

How Dangerous Is Product dose omission issue From ANIFROLUMAB?

Of the 12 reports, 6 (50.0%) required hospitalization.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ANIFROLUMAB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does ANIFROLUMAB Cause?

Off label use (33) Systemic lupus erythematosus (31) Drug ineffective (26) Fatigue (19) Arthralgia (18) Pyrexia (18) Covid-19 (17) Cough (16) Headache (16) Lupus nephritis (16)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which ANIFROLUMAB Alternatives Have Lower Product dose omission issue Risk?

ANIFROLUMAB vs ANIFROLUMAB-FNIA ANIFROLUMAB vs ANIFROLUMAB\ANIFROLUMAB-FNIA ANIFROLUMAB vs ANTHOXANTHUM ODORATUM POLLEN\DACTYLIS GLOMERATA POLLEN\LOLIUM PERENNE POLLEN\PHLEUM PRATENSE POLLEN\POA PRATENSIS POLLEN ANIFROLUMAB vs ANTI-INHIBITOR COAGULANT COMPLEX ANIFROLUMAB vs ANTIHEMOPHILIC FACTOR HUMAN

Related Pages

ANIFROLUMAB Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue ANIFROLUMAB Demographics